BioWorld has been acquired by Thomson Reuters
BioWorld, the daily biopharmaceutical news source, has been acquired by Thomson Reuters, the world's leading source of intelligent information for businesses and professionals. By joining Thomson Reuters, BioWorld will have more opportunity to further invest in innovation and to grow its offerings.
As you may know, Thomson Reuters is the provider of Cortellis. Thomson Reuters CortellisSM is a single source of pharmaceutical intelligence with flexible delivery options for quicker, more-informed decision making. Bringing the BioWorld portfolio into Thomson Reuters will strengthen BioWorld's publications by giving the journalists access to all the information Thomson Reuters captures on the industry. The news and industry perspective published by BioWorld will likewise strengthen the information, analytics and insight Thomson Reuters delivers to its customers.
BioWorld customers will further benefit from Thomson Reuters' superior service, global resources and rich expertise along with integrated access to a broad range of content including: clinical trials, pharmacology, systems biology, patents, investigational drugs, and conference reports.
BioWorld and Thomson Reuters are both delighted by this new opportunity. Should you have any questions about this, please do not hesitate to call us at 1-800-336-4474 or 1-215-386-0100 or send an email to email@example.com
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter